Hemostasis changes during veno-venous extracorporeal membrane oxygenation for respiratory support in adults

Minerva Anestesiologica

Volumn 82, Issue 2, 2016, Pages 170-179

  Panigada, Mauro ^a   Artoni, Andrea ^a   Passamonti, Serena M ^a   Maino, Alberto ^a   Mietto, Cristina ^a   L'acqua, Camilla ^a   Cressoni, Massimo ^a   Boscolo, Massimo ^a   Tripodi, Armando ^a   Bucciarelli, Paolo ^a   Gattinoni, Luciano ^a   Martinelli, Ida ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Anticoagulants therapy; Blood coagulation; Extracorporeal Membrane Oxygenation; Heparin; Partial Thromboplastin Time

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 8; D DIMER; FIBRINOGEN; FRESH FROZEN PLASMA; HEPARIN; PROTHROMBIN; PROTHROMBIN FRAGMENT 1; PROTHROMBIN FRAGMENT 2; RISTOCETIN; THROMBIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ANTICOAGULANT AGENT;

ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; BRAIN HEMORRHAGE; CENTRIFUGAL PUMP; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG MONITORING; ECHOGRAPHY; ENDOGENOUS THROMBIN POTENTIAL; EXTRACORPOREAL MEMBRANE OXYGENATION DEVICE; EXTRACORPOREAL OXYGENATION; FEMALE; FIBRIN FORMATION; FIBRINOGEN BLOOD LEVEL; FLUOROMETER; HEMATOLOGICAL PARAMETERS; HEMOSTASIS; HEMOSTASIS TESTING SYSTEM; HEPARINIZATION; HUMAN; IMAGING SOFTWARE; INTENSIVE CARE; INTERMETHOD COMPARISON; KAOLIN ACTIVATED THROMBOELASTOGRAPHY; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MOLECULAR WEIGHT; MORTALITY RATE; PARTIAL THROMBOPLASTIN TIME; PHARYNX HEMORRHAGE; PILOT STUDY; PLASMA TRANSFUSION; PNEUMONIA; PROTEIN FUNCTION; PULMONARY SHUNT; RETROPERITONEAL HEMORRHAGE; RETROPHARYNGEAL HEMORRHAGE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOELASTOGRAPHY; TREATMENT DURATION; VERY ELDERLY; ARTIFICIAL VENTILATION; BLOOD; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY DISTRESS SYNDROME, ADULT; RESPIRATORY INSUFFICIENCY;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT; RESPIRATORY INSUFFICIENCY;

EID: 84959859701     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): A multicentre randomised controlled trial. Lancet 2009;374:1351-63.
2. Brogan TV, Thiagarajan RR, Rycus PT, Bartlett RH, Bratton SL. Extracorporeal membrane oxygenation in adults with severe respiratory failure: A multi-center database. Intensive Care Med 2009;35:2105-14.
3. Oliver WC. Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth 2009;13:154-75.
4. Paden ML, Conrad SA, Rycus PT, Thiagarajan RR, ELSO Registry. Extracorporeal life support organization registry report 2012. ASAIO J 2013;59:202-10.
5. Davies A, Jones D, Bailey M, Beca J, Bellomo R, Blackwell N, et al. Extracorporeal membrane oxygenation for 2009 influenza A (H1N1) acute respiratory distress syndrome. JAMA 2009;302:1888-95.
6. Plötz FB, van Oeveren W, Bartlett RH, Wildevuur CR. Blood activation during neonatal extracorporeal life support. J Thorac Cardiovasc Surg 1993;105:823-32.
7. Heilmann C, Geisen U, Beyersdorf F, Nakamura L, Benk C, Trummer G, et al. Acquired von willebrand syndrome in patients with extracorporeal life support (ECLS). Intensive Care Med 2012;38:62-8.
8. Tauber H, Ott H, Streif W, Weigel G, Loacker L, Fritz J, et al. Extracorporeal membrane oxygenation induces short-Term loss of high-molecular-weight von willebrand factor multimers. Anesth Analg 2015;120:730-6.
9. Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemosta sis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010;8:202-4.
10. Napolitano LM, Warkentin TE, Almahameed A, Nasraway SA. Heparin-induced thrombocytopenia in the critical care setting: Diagnosis and management. Crit Care Med 2006;34:2898-911.
11. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, et al. Inherited thrombophilia: Part 1. Thromb Haemost 1996;76:651-62.
12. Arkel YS, Paidas MJ, Ku DH. The use of coagulation activation markers (soluble fibrin polymer, tpp, prothrombin fragment 1.2, thrombin-Antithrombin, and d-dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders. Blood Coagul Fibrinolysis 2002;13:199-205.
13. Federici AB, Canciani MT, Forza I, Mannucci PM, Marchese P, Ware J, Ruggeri ZM. A sensitive ristocetin co-factor activity assay with recombinant glycoprotein ibalpha for the diagnosis of patients with low von willebrand factor levels. Haematologica 2004;89:77-85.
14. ELSO guidelines for cardiopulmonary extracorporeal life support. Extracorporeal life support organization, version 1.3 november 2013; [Internet]. Available at: Http://Http://www.elsonet.org/index.php?Option=com-phocadownload&view=category&download=17:elsoguidelines-generalv11&id=4:guidelines&itemid=627 [cited 2014, Jun 4].
15. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-9.
16. Garcia DA, Baglin TP, Weitz JI, Samama MM, American College of Chest Physicians. Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidencebased clinical practice guidelines. Chest 2012;141(2 Suppl):e24S-43S.
17. Bull MH, Huse WM, Bull BS. Evaluation of tests used to monitor heparin therapy during extracorporeal circulation. Anesthesiology 1975;43:346-53.
18. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003;33:4-15.
19. Uziel L, Cugno M, Fabrizi I, Pesenti A, Gattinoni L, Agostoni A. Physiopathology and management of coagulation during long-Term extracorporeal respiratory assistance. Int J Artif Organs 1990;13:280-7.
20. Lubnow M, Philipp A, Dornia C, Schroll S, Bein T, Creutzenberg M, et al. D-dimers as an early marker for oxygenator exchange in extracorporeal membrane oxygenation. J Crit Care 2014;29:473.e1-5.
21. Dietrich W, Braun S, Spannagl M, Richter JA. Low preoperative antithrombin activity causes reduced response to heparin in adult but not in infant cardiac-surgical patients. Anesth Analg 2001;92:66-71.
22. Urlesberger B, Zobel G, Zenz W, Kuttnig-Haim M, Maurer U, Reiterer F, et al. Activation of the clotting system during extracorporeal membrane oxygenation in term newborn infants. J Pediatr 1996;129:264-8.
23. Hundalani SG, Nguyen KT, Soundar E, Kostousov V, Bomgaars L, Moise A, et al. Age-Based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation. Pediatr Crit Care Med Nguyen KT, Soundar E, Kostousov V, Bomgaars L, Moise A.
24. Bembea MM, Schwartz JM, Shah N, Colantuoni E, Lehmann CU, Kickler T, et al. Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. ASAIO J 2013;59:63-8.
25. Arnold P, Jackson S, Wallis J, Smith J, Bolton D, Haynes S. Coagulation factor activity during neonatal extracorporeal membrane oxygenation. Intensive Care Med 2001;27:1395-400.
26. Green TP, Isham-Schopf B, Irmiter RJ, Smith C, Uden DL, Steinhorn RH. Inactivation of heparin during extracorporeal circulation in infants. Clin Pharmacol Ther 1990;48:148-54.
27. Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg 1978;26:231-40.
28. Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Spitznagel E, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994;108:1076-82.
29. Martindale SJ, Shayevitz JR, DErrico C. The activated coagulation time: Suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery. J Cardiothorac Vasc Anesth 1996;10:458-63.
30. Liveris A, Bello RA, Friedmann P, Duffy MA, Manwani D, Killinger JS, et al. Antifactor xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med 2014;15:e72-9.
31. Ranucci M, Baryshnikova E, Isgrò G, Carlucci C, Cotza M, Carboni G, Ballotta A. Heparin-like effect in postcardiotomy extracorporeal membrane oxygenation patients. Crit Care 2014;18:504.
32. Combes A, Bacchetta M, Brodie D, Möller T, Pellegrino V. Extracorporeal membrane oxygenation for respiratory failure in adults. Curr Opin Crit Care 2012;18:99-104.
33. Protti A, Fortunato F, Caspani ML, Pluderi M, Lucchini V, Grimoldi N, et al. Mitochondrial changes in platelets are not related to those in skeletal muscle during human septic shock. PLoS One 2014;9:e96205.